BLA 761309 · Genentech INC
Columvi
Glofitamab-Gxbm · Injection · Bispecific CD20-directed CD3 T Cell Engager
NovelAccelerated approvalPriority reviewCDER novel approval, Jun 15, 2023: To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jun 15, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
90
4 Phase 3, 43 recruiting
FAERS reports
2,709
2,487 serious, 781 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI. Premedicate before each dose, and initiate treatment with the COLUMVI step-up dosing schedule to reduce the risk of CRS. Withhold COLUMVI until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.3 , and 2.4) and Warnings and Precautions (5.1) ] . WARNING: CYTOKINE RELEASE SYNDROME See full prescribing information for complete boxed warning Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI. Premedicate before each dose, and initiate treatment with the COLUMVI step-up dosing schedule to reduce the risk of CRS. Withhold COLUMVI until CRS resolves or permanently discontinue based on severity. ( 2.1 , 2.2 , 2.3 , 2.4 , 5.1 )
What it is approved for
From the label in effect Jun 25, 2026.
COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). COLUMVI is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Glofitamab-gxbm is a bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 receptor expressed on the surface of T cells. Glofitamab-gxbm causes T-cell activation and proliferation, secretion of cytokines, and the lysis of CD20-expressing B cells. Glofitamab-gxbm showed anti-tumor activity in vivo in mouse models of DLBCL.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 15, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelLetterReview
2 products under this application
- COLUMVI · GLOFITAMAB-GXBM 10MG/10ML(1MG/ML) · INJECTABLE, INJECTION · Prescription
- COLUMVI · GLOFITAMAB-GXBM 2.5MG/2.5ML(1MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Glofitamab" as an intervention, any sponsor and status, largest first.
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06047080 · 1,130 participants · Start Sep 18, 2023 · Primary completion Oct 1, 2027
Drug: Glofitamab; Polatuzumab vedotin and 4 more · For: Large B-Cell Lymphoma
Sites: Anchorage, Alaska; Anaheim, California; Clovis, California · 229 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03075696 · 940 participants (planned) · Start Feb 21, 2017 · Primary completion Mar 30, 2029
Drug: Glofitamab; Obinutuzumab and 1 more · For: Non-Hodgkin's Lymphoma
Sites: Ann Arbor, Michigan; St Louis, Missouri; New York, New York · 34 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04077723 · 498 participants (planned) · Start Aug 13, 2019 · Primary completion Dec 28, 2026
Drug: Englumafusp alfa; Obinutuzumab and 2 more · For: Lymphoma, Non-Hodgkin
Sites: Pasadena, California; San Francisco, California; St Louis, Missouri · 35 sites in all
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06090539 · 460 participants (planned) · Start Dec 29, 2023 · Primary completion Oct 28, 2027
Drug: BMS-986458; Rituximab and 4 more · For: Relapsed/Refractory Non-Hodgkin Lymphoma
Sites: Phoenix, Arizona; Duarte, California; Jacksonville, Florida · 76 sites in all
Arvinas Inc.Industry
NCT06393738 · 329 participants (planned) · Start Sep 5, 2024 · Primary completion Mar 2028
Drug: ARV-393; Glofitamab · For: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Sites: New Haven, Connecticut; Miami, Florida; Detroit, Michigan · 21 sites in all
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07724457 · 271 participants (planned) · Start Jul 27, 2027 · Primary completion Nov 1, 2033
Drug: Carboplatin; Cyclophosphamide and 11 more · For: Recurrent Burkitt Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory Burkitt Lymphoma and 1 more
Sites: Chicago, Illinois
- A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04408638 · 270 participants (planned) · Start Feb 23, 2021 · Primary completion Mar 31, 2028
Drug: Obinutuzumab; Glofitamab and 4 more · For: Diffuse Large B-cell Lymphoma
Sites: Birmingham, Alabama; Fresno, California; Jacksonville, Florida · 63 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03533283 · 211 participants · Start May 8, 2018 · Primary completion Oct 22, 2026
Drug: Glofitamab; Atezolizumab and 4 more · For: Non-Hodgkins Lymphoma
Sites: Charlotte, North Carolina; Ghent, Belgium; Aarhus N, Denmark · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome855
- disease progression486
- off label use325
- death304
- pyrexia221
- neutropenia198
- immune effector cell-associated neurotoxicity syndrome156
- covid-19126
- anaemia115
- infection114
- febrile neutropenia107
- pneumonia102
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 8 |
| 2021 | 60 |
| 2022 | 161 |
| 2023 | 293 |
| 2024 | 639 |
| 2025 | 690 |
| 2026 | 851 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Columvi (Glofitamab-Gxbm) · HCPCS J9286
2024 spending
$41.1M
Beneficiaries
280
1,451 claims
Per beneficiary
$146,787
2024 ASP limit $2,705.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $41,100,316 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Abramson JS, Ku M, Hertzberg M, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
Sam J, Leclercq-Cohen G, Gebhardt S, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Phillips TJ, Carlo-Stella C, Morschhauser F, et al. · J Clin Oncol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.
Abramson JS, Townsend W, Fox CP, et al. · Blood Adv 2026 · Clinical Trial, Phase III, Multicenter Study
- Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
Frances N, Bacac M, Bray-French K, et al. · J Pharm Sci 2022 · Research Support, Non-U.S. Gov't, Clinical Trial, Phase II
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.